Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bacillus anthracis and antibacterial agents.

A Bryskier1

  • 1Aventis Pharma SA, Infectious Disease Group, Romainville, France. andre.bryskier@aventis.com

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|August 29, 2002
PubMed
Summary

Anthrax treatment requires potent antibiotics like doxycycline and fluoroquinolones, effective against bacteria and toxins. Further research is needed for macrolides and ketolides in anthrax therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibacterial drug discovery and development--third international summit. 8-9 March 1999, Princeton, NJ, USA.

IDrugs : the investigational drugs journal·2005
Same author

Novelties in the field of fluoroquinolones.

Expert opinion on investigational drugs·2005
Same author

New research in macrolides and ketolides since 1997.

Expert opinion on investigational drugs·2005
Same author

Dual beta-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment.

Expert opinion on investigational drugs·2005
Same author

Novelties in the field of macrolides.

Expert opinion on investigational drugs·2005
Same author

Mechanisms of macrolide resistance in clinical pneumococcal isolates in a university hospital, Ankara, Turkey.

Journal of chemotherapy (Florence, Italy)·2005

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Anthrax remains an endemic threat in animals globally, posing risks for human infection, including potential bioterrorism.
  • Effective treatment strategies for anthrax are crucial, especially for severe systemic cases.

Purpose of the Study:

  • To review current knowledge on the antibacterial activity of available antibiotics against Bacillus anthracis.
  • To identify antibiotics with potent in vitro and intracellular activity suitable for anthrax treatment.

Main Methods:

  • Literature review of studies on antibiotic efficacy in anthrax.
  • Analysis of in vitro and animal model data for various antibiotic classes.

Main Results:

Related Experiment Videos

  • Doxycycline and fluoroquinolones demonstrate significant activity in animal models for anthrax.
  • Macrolides and ketolides show good in vitro activity, but data in animal models is limited.
  • Systemic anthrax is primarily caused by toxin, necessitating anti-intoxication therapies.

    • Conclusions:

    • Doxycycline and fluoroquinolones are promising for anthrax treatment due to their proven efficacy.
    • Further investigation into macrolides and ketolides in anthrax models is warranted.
    • Adjunctive anti-toxin therapy is essential for managing severe systemic anthrax.